Thiopurine Treatment in Inflammatory Bowel Disease: Clinical Pharmacology and Implication of Pharmacogenetically Guided Dosing

By Teml Alexander  

Clinical Pharmacokinetics, Vol. 46, Iss. 3, 2007-01 ,pp. : 187-208

Adis International

Access to resources Recommend Favorite

Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs

By Sheffield Leslie J   Irving Peter   Gupta Arun   Byron Keith   Macrae Finlay A   Phillimore Hazel   Dronavalli Mithilesh   Rose Rosemary   George Peter   Walmsley Trevor   Dixon Barbara   Poole Susan   Dooley Michael   Sparrow Miles  

Pharmacogenomics, Vol. 10, Iss. 7, 2009-07 ,pp. : 1091-1099

Future Medicine

Access to resources Recommend Favorite

Allopurinol–thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?

By Roberts Rebecca L   Gearry Richard B   Barclay Murray L  

Pharmacogenomics, Vol. 11, Iss. 11, 2010-11 ,pp. : 1505-1508

Future Medicine

Access to resources Recommend Favorite

Mesalazine for the treatment of inflammatory bowel disease

By Criscuoli Valeria  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1669-1678

Informa Healthcare

Access to resources Recommend Favorite

New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients

By Zabala William   Cruz Raquel   Barreiro-de Acosta Manuel   Chaparro María   Panes Julián   Echarri Ana   Esteve Maria   Carpio Daniel   Andreu Montserrat   García-Planella Esther   Domenech Eugeni   Carracedo Angel   Gisbert Javier P   Barros Francisco  

Pharmacogenomics, Vol. 14, Iss. 6, 2013-04 ,pp. : 631-640

Future Medicine

Access to resources Recommend Favorite